Imovax Rabies Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Imovax Rabies market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to increased awareness of rabies prevention, growing government initiatives, a rise in the prevalence of dog bites, initial acceptance by healthcare providers, and the growing population of stray dogs.

The projected growth during the forecast period can be attributed to patient access initiatives, expanded indications, increased pet adoption, global market penetration, and a rising number of animal-related activities. Key trends expected during this period include expanded vaccination programs, the development of thermostable vaccines, technological advancements in vaccine production, product innovations, and growing funding for research.

The increase in rabies cases is expected to drive the growth of the Imovax rabies market in the coming years. Rabies is an infection caused by the rabies virus, typically spread through animal bites, leading to severe neurological symptoms and often death if left untreated. The rise in rabies cases is largely due to increased human-animal interactions, insufficient vaccination of pets, and limited access to timely medical treatment in certain areas. Imovax rabies works by stimulating the immune system to produce antibodies against the virus, preventing the onset of rabies after exposure. For example, in April 2024, the South Dakota Department of Health reported that in 2023, 20 animals in South Dakota were confirmed to have rabies, a 122% increase from 9 cases in 2022. As a result, the growing number of rabies cases is fueling the demand for Imovax rabies.

The growing number of animal-related activities is also expected to support the growth of the Imovax rabies market. These activities involve animals in research, experimentation, breeding, and genetic modification. The rise in such activities is driven by factors such as an increased interest in outdoor recreation, urban expansion into wildlife habitats, and the popularity of pet ownership. Imovax rabies is commonly used in these activities for research and the development of vaccines to control and prevent rabies in both humans and animals. For instance, Understanding Animal Research, a UK-based organization, reported that in 2022, there were 2,764,204 experimental procedures in Great Britain, including 1,512,210 for experimental purposes and 1,248,994 for breeding genetically altered animals. This increase in animal-related activities contributes to the growth of the Imovax rabies market.

The rise in pet ownership is another factor driving the expansion of the Imovax rabies market. More people are adopting pets due to increased awareness of pet care, changing lifestyles, and stronger human-animal bonds. Imovax rabies is used in pets for both post-exposure prophylaxis and pre-exposure vaccination to protect against rabies. For example, in October 2023, the American Pet Products Association reported that 86.9 million U.S. households owned a pet, representing 66% of households in 2022. Similarly, in November 2022, Animal Medicines Australia reported that 69% of Australian households owned pets. This growing trend in pet adoption is fueling the demand for Imovax rabies.

The key player in the imovax rabies market is Sanofi SA.

North America was the largest region in the imovax rabies market in 2024. The regions covered in imovax rabies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the imovax rabies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Imovax Rabies is an inactivated rabies vaccine designed to prevent rabies infection in humans. It is typically administered as a series of intramuscular injections, either as pre-exposure prophylaxis for individuals at high risk or post-exposure prophylaxis following potential rabies exposure, such as a bite from a potentially rabid animal.

The primary patient demographics for Imovax Rabies include pediatric patients, adult patients, and high-risk groups. Pediatric patients are children who may be at risk of rabies due to animal bites or travel to areas where rabies is common. These children may require specific dosages and treatments for rabies prevention, and Imovax Rabies offers vaccines tailored for young patients. The vaccine is distributed through various channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies, for use in both post-exposure and pre-exposure prophylaxis.

The imovax rabies market research report is one of a series of new reports that provides imovax rabies market statistics, including the imovax rabies industry's global market size, regional shares, competitors with a imovax rabies market share, detailed imovax rabies market segments, market trends and opportunities, and any further data you may need to thrive in the imovax rabies industry. This imovax rabies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The imovax rabies market consists of sales of rabies vaccine inactivated (DCO). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.